Acute Effect of Imeglimin Add-on Therapy on 24-h Glucose Profile and Glycemic Variability in Patients with Type 2 Diabetes Receiving Metformin
Imeglimin add-on therapy to metformin acutely lowered 24-h glucose levels and improved glycemic variability in patients with type 2 diabetes on metformin. A higher serum HDL cholesterol at baseline was associated with a better response to acute effects of imeglimin on 24-h glucose levels and glycemic variability.
Authors
- Yoshimasa Aso (ORCID: https://orcid.org/0000-0003-0610-1999)
- Shintaro Sakurai (ORCID: https://orcid.org/0009-0003-9689-9363)
- Takuya Tomaru (ORCID: https://orcid.org/0000-0003-0850-5655)
- Toshie Iijima (ORCID: https://orcid.org/0000-0002-4613-3744)
- Teruo Inoue (ORCID: https://orcid.org/0000-0002-5915-2282)
- I Akutsu
- Yasutake Shinohara
- Isao Usui (ORCID: https://orcid.org/0000-0002-4720-4882)
- Teruo Jojima
- Yusuke Kamiga
Institutions
- Dokkyo Medical University (JP)
Publication Details
- Journal
- Medical Principles and Practice
- Published
- 2024-08-12
- DOI
- https://doi.org/10.1159/000540852
- Citations
- 3
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.07